Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

NCT01416428 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

210

Enrollment

INDUSTRY

Sponsor class

Stopped A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.

Conditions

Multiple Myeloma
Waldenstrom Macroglobulinemia

Interventions

DRUG: oprozomib

Sponsor

Amgen